Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lowering LDL cholesterol. How much is enough?].

W März1, T B Grammer

  • 1Synlab Medizinisches Versorgungszentrum für Labordiagnostik Heidelberg, Heidelberg, Deutschland. maerz@synlab.de

Der Internist
|March 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Lipoprotein (a) on the Quantification of LDL-Cholesterol.

Clinical laboratory·2026
Same author

[Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations].

Innere Medizin (Heidelberg, Germany)·2023
Same author

NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients.

European heart journal open·2023
Same author

NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study.

International journal of cardiology. Heart & vasculature·2020
Same author

[Congenital disorders of lipoprotein metabolism].

Herz·2017
Same author

[Management of different cardiovascular risk factors with a combination tablet (polypill)].

Herz·2017
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Lowering LDL cholesterol (LDL-C) significantly reduces cardiovascular risk, especially for high-risk patients. Lipid-lowering therapy is most effective when tailored to individual patient risk levels for arteriosclerosis prevention.

Area of Science:

  • Cardiovascular Medicine
  • Lipidology
  • Arteriosclerosis Research

Context:

  • Arteriosclerosis presents a significant health challenge, with cholesterol management being a key principle in its prevention and treatment.
  • Lipid-lowering pharmacotherapy effectiveness is directly correlated with individual patient risk.
  • Therapeutic decisions for lipid management are guided by a comprehensive assessment of the patient's overall risk profile.

Purpose:

  • To outline the established benefits of reducing cholesterol and low-density lipoprotein cholesterol (LDL-C) in managing arteriosclerosis.
  • To define target LDL-C levels for different patient populations, including those with acute coronary syndrome, diabetes mellitus, and stable coronary heart disease.
  • To discuss the role of diabetes mellitus as a potential coronary risk equivalent.

Related Experiment Videos

Summary:

  • Significant reduction of LDL-C to approximately 70 mg/dl over time can decrease coronary event risk by two-thirds.
  • For patients with acute coronary syndrome and/or diabetes mellitus, an LDL-C target of 70 mg/dl is clinically justified.
  • For patients with stable coronary heart disease, aiming for an LDL-C level of 100 mg/dl or lower is recommended.
  • The classification of diabetes mellitus as a "coronary risk equivalent" warranting an LDL-C reduction to 100 mg/dl or less remains a subject of debate.

Impact:

  • Provides clear targets for LDL-C reduction to mitigate arteriosclerosis and coronary events.
  • Informs clinical decision-making regarding the intensity of lipid-lowering pharmacotherapy based on patient risk stratification.
  • Highlights areas for further research regarding the precise management of dyslipidemia in diabetic patients.